Hinge Bio specializes in leveraging its proprietary Flex-Hinge antibody platform to develop bispecific and multispecific antibodies.
Hinge Bio has raised $30.0M in total funding. The most recent round was Series A. The last funding was announced in January 2025.
Hinge Bio's investors include National Science Foundation, Point72, Agent Capital, InVivium Capital, Lightswitch Capital.
Hinge Bio is headquartered in Burlingame, United States.
Hinge Bio specializes in leveraging its proprietary Flex-Hinge antibody platform to develop bispecific and multispecific antibodies.
Hinge Bio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Hinge Bio — Funding & Investors." VCBacked, January 15, 2025, https://www.vcbacked.co/company/hinge-bio. Accessed July 27, 2026.
VCBacked. (2025). Hinge Bio — Funding & Investors. Retrieved July 27, 2026, from https://www.vcbacked.co/company/hinge-bio
{{cite web |title=Hinge Bio — Funding & Investors |url=https://www.vcbacked.co/company/hinge-bio |website=VCBacked |access-date=July 27, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated